Dependence and Guidance Receptors—DCC and Neogenin—In Partial EMT and the Actions of Serine Proteases

Trevor W. Stone*

NDORMS, University of Oxford, Oxford, United Kingdom

The Epithelial-Mesenchymal Transition (EMT) is an important concept in understanding the processes of oncogenesis, especially with respect to the relationship between cell proliferation and metastatic properties such as spontaneous cell motility, chemotactic migration and tissue invasion. EMT is now recognized as a more complex phenomenon than an all-or-nothing event, in which different components of the EMT may have distinct roles in the physio-pathological regulation of cell function and which may in turn depend on differential interactions with cell constituents and metabolic products. This mini-review summarizes recent work on the induction of cancer properties in parallel with the presence of EMT activities in the presence of serine proteases, with the focus on those tumor suppressors known as “dependence” receptors such as neogenin and Deleted in Colorectal Cancer (DCC). It is concluded that various forms of partial EMT should be given more detailed investigation and consideration as the results could have valuable implications for the development of disease-specific and patient-specific therapies.

Keywords: DCC, neogenin, chymotrypsin, subtilisin, serine proteases

INTRODUCTION

The concept of Epithelial-Mesenchymal Transition (EMT) was founded on changes in adhesion molecules associated with proliferation, cell dis-association, de-differentiation to a more mesenchymal stem cell character and the establishment of a motile, potentially invasive phenotype (1). EMT was thought necessary to initiate cell departure from a home tissue, a phenomenon seen in embryogenesis and in the metastatic spread of cancers. Recent studies have begun to define “partial” forms of EMT while others propose that EMT is more concerned with the end-stages of migration and invasion, with the reverse process of MET being at least as important as EMT (2, 3). EMT may be critical to the physical stabilization of cells in a metastatic location and in the development of increased resistance to chemotherapeutic drugs. The role of EMT in carcinogenesis may generate new sets of biomarkers for early metastasis detection and novel targets for dedicated drug development.

The complexity of molecular changes associated with EMT was responsible for the proposal of sub-types of EMT, or “partial” EMT, and the possibility that different molecular profiles may relate to the activity and aggressiveness of tumors. Partial EMTs may take many forms, based on different molecular profiles which characterize different cell types, tissue locations and pathological conditions. The concept predicts that partial EMTs may provide a key for the generation of individual, tissue and disease specificity necessary for developing successful
personalized therapy of cancers and other disorders. Defining the factors which induce partial EMTs will be essential if these relationships are to be exploited therapeutically. This mini-review surveys evidence for a role, in these events, of Dependence Receptors and their modulation by serine proteases.

**DEPENDENCE AND GUIDANCE RECEPTORS (DGRs)**

The Dependence Receptors include Deleted in Colorectal Carcinoma (DCC) and the structurally related molecule neogenin (49% amino acid identity) (4). The term “dependence” receptors indicates that cell viability depends on ligation of the receptors by extracellular ligands such as the netrin family of extracellular proteins (ligands for DCC and neogenin) (5–8) or the Repulsive Guidance Molecules (RGMs; ligands for neogenin only). When occupied the receptors maintain cell survival, restraining cells from initiating apoptotic death when deprived of their ligands (9, 10) (Figure 1). These same receptors play crucial “guidance” roles, influencing the direction and rate of cell movement and the direction and size of cell outgrowths such as lamellipodia. These actions are seen in embryonic development when the dependence receptors guide progenitor cells to their eventual locations (11, 12), and in the developing and adult nervous system where they influence axonal or dendritic growth as well as the positioning of newly formed neurons (13–16), synaptic contacts and neural plasticity (17, 18). In view of this functional duality, the receptors will be referred to as Dependence and Guidance Receptors (DGRs).

Also of relevance to EMT is the unco-ordinated-5 (unc5) family of DGRs—homologs of the uncoordinated locomotion genes in *Caenorhabditis elegans*—which also bind netrins as ligands (19). The binding of netrin-1 to DCC normally induces growth toward the focus of netrin production (20). If DCC is absent and netrin binds to unc5, then the result is repulsion: cells are directed away from the site of highest netrin concentration. Interaction between the intracellular domains of DCC and unc5 converts DCC attraction to repulsion (21). It would seem very likely that the migratory drive, direction and eventual target relocation of cells bearing these DGRs will depend on the ratios of attractant and repellent molecular states and may be critical in the establishment of metastases.

**Relationships Between DGRs and EMT**

Cell dependence on DGRs may have evolved in response to the development of multicellularity and distinct tissues. A cell could develop a genetic mutation spontaneously or induced by an event that alters the balance of attractant and repellent ligands on the cell surface. In this way, DCC and neogenin may act as checkpoints for the development and maintenance of normal tissue architecture. Conversely, the binding of netrins to DCC and neogenin may prevent cells from adopting an aggressive, pro-migratory phenotype. The netrin-DCC interaction is required for cell migration and survival, and its disruption can lead to cell death. The netrin-DCC interaction also regulates the activation of downstream signaling pathways, such as the Rho family of GTPases, which control cell morphology and motility.

![Serine proteases, Dependence Receptors and EMT](image)

**Figure 1** The DGRs, serine proteases, and EMT. A diagrammatic summary of the relationship between the DGRs DCC and neogenin, serine proteases, and the initiation of EMT. (A) If un-restrained by ligand binding, the DGRs promote cell death. (B) The primary ligands of DCC and neogenin are the netrin proteins, which restrain their ability to induce apoptosis. (C) Conversely the DGRs exert a feedback restraint on the netrins which tend to drive cells into an aggressive, pro-migratory mode via the induction of EMT. (D) The serine proteases chymotrypsin and subtilisin deplete DCC and neogenin from cells, allowing netrin to drive EMT and migration. (E) The classical EMT involves changes in the absolute and relative levels of proteins such as those indicated, but the magnitude and direction of change depends on the cell type, inducing stimulus, local microenvironment, and physio-pathological status, yielding a plethora of possible combinations of change which could represent highly selective therapeutic targets.
infective organism, toxic compounds or physical trauma, which reduced intercellular adhesion—a necessary early stage of cell dis-association needed for EMT. A cell which becomes detached from the home tissue will then enter the extracellular medium as a free-living, migratory cell. The potential for early stage cancerous cells to establish metastatic colonies is clear. However, after leaving the home tissue the fall in ligand concentration for the cell’s DGRs induces the unbound receptors to promote caspase-mediated apoptotic death (anoikis) (9, 22), a result which has been considered a safety mechanism to minimize or prevent the development of metastases.

In some cases, cells could become established at sites where a sufficient concentration of netrin isoforms allows them to create a new micro-colony (metastasis), since many tissues are able to synthesize and secrete these proteins (23–26). This may require the migration of a minimum number of cells which, once established, could produce enough ligand to maintain the metastatic colony. If this hypothesis were correct, it would suggest the need to inhibit tumor development as early as possible to prevent metastatic deposits achieving a size at which their ligand production offers continuing survival.

We have shown that DGR function may be regulated by chymotryptic serine proteases which deplete cells of their DGRs, causing increased cell migration (27), actions that may contribute to dietary effects on cancer incidence (28, 29). Subsequently, the effects of this DGR loss on the induction and progression of EMT were considered to identify any relationship between them, as discussed in the following sections in which the major EMT proteins E-cadherin, N-cadherin, β-catenin and vimentin were investigated (Figure 1) (30).

E-Cadherin
E-cadherin is localized primarily to cell membranes where it is involved in the formation of intercellular adherens junctions. It is considered a marker for resting, physiologically stable epithelial cells and its levels fall as cells de-differentiate before adopting the metabolic and morphological characteristics of migratory cells (31–35). In contrast, N-cadherin expression usually increases with the approaching onset of EMT and migration (36). The depletion of E-cadherin has been associated with carcinogenesis and metastasis formation (34, 37–39) and there is moderate expression in potentially metastatic cells. It has been shown that high levels of E-cadherin occur in metastases but it is absent from many primary tumors (40, 41).

β-Catenin
E-cadherin is usually associated with β-catenin and loss of the former releases β-catenin to enter the cytosol and nucleus where, as part of the wingless (Wnt) pathway, it regulates gene expression to influence proliferation and migration (31, 38, 41–54). It has been considered as the most significant protein characterizing EMT (55–60). However, β-catenin activation has also been linked to an inhibition of cell growth (61) and in some cases has little effect on cell behavior (62) while around 30% of mammary cancer cells had little or no β-catenin, raising questions about the extent and timing of its involvement in tumor development (63). β-catenin may have other functions in the cell independent of proliferation or migration, including the maintenance of epithelial structure and differentiation (51).

Vimentin
Vimentin is a microfilament protein involved in cytoskeletal function. As EMT develops, vimentin levels increase with cytoskeletal reorganization required for migration (64–68). In the absence of vimentin, migration is significantly reduced (69) as the E-cadherin/vimentin ratio may determine the switch from low to high invasion capacity. Transforming Growth Factor-β, a major regulator of EMT, may regulate vimentin expression and the decrease in E-cadherin (70, 71). However, vimentin is not always increased in migratory cells (72) and simple changes in incubation conditions, such as reducing the proportion of serum, can induce vimentin expression (27, 30). Vimentin expression might therefore be linked to the differentiation state of cells rather than their migratory status or capacity (73).

Serine Proteases, DGRs, and Partial EMT
Contradictory results have also been described when cells were exposed to serine proteases such as mammalian chymotrypsin or the bacterial chymotryptic enzyme subtilisin (27, 30). These proteases reduced expression of DCC and neogenin, with changes in the EMT proteins that were not consistent with normal views on their relationship to EMT. In particular, while levels of E-cadherin were reduced with the onset of migration, β-catenin levels were unaffected or substantially reduced, observations also obtained by other groups (45, 74). Vimentin expression was increased, as would be predicted for a compound involved in cytoskeletal adaptations to a change in differentiation state, dissociation and migration.

This pattern of protein changes associated with a loss of DGRs is clearly different from classical descriptions of EMT, suggesting that DGR loss should be added to the list of phenomena able to induce a “partial” EMT. Similar results have been obtained by silencing the neogenin gene in the absence of other primary modifications (75). This selective loss of neogenin also provoked changes in EMT proteins which were not fully consistent with conventional views of EMT leading to the conclusion that (from genetic and morphological data), a “partial EMT” was produced. Importantly, the results not only extend our own work but also confirm that the serine protease effects were probably produced solely by actions involving DGRs.

With the growing recognition of partial EMTs (76–83) some initiating factors are being identified including phosphatidylinositol-3-kinase (84), TGF-β (85–87), galectins (88), or altered expression of PTEN (89). Some groups define partial EMT with respect to mismatch between cell protein profile and phenotypic behavior (90) while others are attempting to define RNA fragments which regulate protein expression. These include miR-376a, miR-381, and miR-128 for which evidence indicates a significant relationship to tumor diagnosis and progression (91).

DGRs, EMT, and Differentiation
DCC expression declines as tumors advance and cells become more de-differentiated (92, 93). This would be consistent with the suggestion that EMT is a reflection of the differentiation status
of cells and might explain the changes in vimentin expression induced by reduced serum-containing media (30, 73). It would account for the loss, rather than increase in β-catenin expression since β-catenin levels fall in cells differentiated by retinoic acid (94). It is also consistent with the need for de-differentiation for cell migration (95).

DCC transfection into cells inhibits proliferation and migration in some cell populations (96–99) but it remains uncertain whether the expression of DGRs such as DCC and neogenin (100) are primary inducers of cancerous change or are secondary contributors to oncogenesis (45, 101–105). The possible association between DCC and the progress of EMT rather than its initiation would be consistent with several studies (103, 106). Perhaps viewing cell differentiation as a key to this uncertainty, rather than the EMT or any individual component of it, may help to resolve the issue (93, 107, 108). DCC is relatively abundant in fully differentiated cells but declines in the early stages of carcinogenesis (109), falling further with advancing tumor stage and reduced patient survival (13, 99, 103, 105, 106, 108, 110–112). Conversely, but very importantly, differentiation induced by a range of factors may only be possible in the presence of DCC (111, 113).

EMT or MET?
A modified view on the link between EMT and differentiation is that EMT may be associated with the termination of cell migration rather than with its initiation. Post-migratory cells undergo changes of EMT proteins which are the reverse of classical EMT changes and which may be crucial for cell re-settlement in a metastatic deposit (114). Interestingly, the loss of protein frazzled (a homolog of DCC) inhibits MET suggesting that DCC may normally drive the non-migratory state of cells by promoting MET, while its progressive decline with tumor growth eventually leads to an apparent EMT and metastatic migration. The netrin ligation of DCC induces a loss of cadherin and the initiation of EMT, raising the possibility that in the absence of netrin, a re-expression of DCC might enhance E-cadherin expression and MET, consolidating metastasis formation (52). Of course, a migrating cell will be identified as a “foreign” cell and will normally be removed by the immune system unless it can re-express DCC. Cells incapable of expressing DCC would remain susceptible to removal unless they migrate to areas sufficiently safely hidden from immune system cells, or where the local concentration of ligand is sufficient to overcome immune attack. These ideas would be consistent with suggestions that DCC increases in later stages of colony formation, when it promotes cell differentiation (with increased E-cadherin). The explanation also accounts for DCC-expressing cells being sensitive to anti-cancer drugs, whereas truly metastatic cells are relatively resistant (2, 3, 115, 116).

CONCLUSIONS
These arguments represent a highly simplified view of molecular events underlying changes in cell properties and behavior. In addition to DGRs, other important factors in EMT include growth factors (especially Transforming Growth Factor-β), oxidative stress, micro-RNAs and immune system cells (macrophages, neutrophils) (117–119). Since neutrophils generate large quantities of chymotryptic serine proteases, they are likely sources of the proteases discussed in this mini-review.

The term “partial EMT” conveys the concept that cells are exhibiting changes which are partially characteristic of epithelial cells and partially typical of mesenchymal cells. On the existing evidence, however, there is likely to be a spectrum of such states, probably dependent on the cell type, preceding mutagenic events and the initial EMT-initiating stimulus (119). It may be that these proteins do not fully describe the intermediate states and the temporal sequence of cell properties, or the protein changes may represent a non-canonical EMT-like process or an independent mechanism for migration. These alternative possibilities might be more consistent with the suggestion that DCC is more functionally related to the stabilization and differentiation aspects of EMT or MET than to migration and metastasis. Indeed, vimentin was the only EMT protein whose expression increased with the increased migration generated by serine proteases. Other descriptions of mixed EMT protein changes include the “transition state” in brain metastases exhibiting atypical expression of E-cadherin and vimentin (32). Thus, vimentin may be a more selective component to study in relation to EMT (120).

Several transcription factors once thought to be essential for EMT are dispensable since, for example, Twist and Snail do not suppress cell invasiveness (2). In addition, EMT proteins may have actions which are unrelated to EMT (121). Overall, however, EMT may contribute to aspects of cell function with changes in protein expression which respond differently to changes in cell status. This could yield cells with a variety of partial “EMT signatures” unique to that cell population, disease and pathology. It is difficult to assess whether EMT is more usefully viewed in terms of the “partial” concept of organizational discontinuity rather than as a continuum of activity (78, 122), since even a continuum of molecular changes may generate discontinuous functional events with different thresholds for switching cell behavior with changes in protein signature. This will be difficult to clarify if those thresholds involve critical ratios of several compounds which individually appear to vary continuously. Nevertheless, developing these could facilitate the development of new anti-cancer therapies with a high degree of specificity and safety for individual patients, cancer type and stage, depending on the cell signature involved. This may be especially important since partial EMTs may be associated with more aggressive and chemoresistant tumors (123–126) although the contrary view has been expressed, emphasizing the need for further work (127).

AUTHOR CONTRIBUTIONS
TS performed the literature search and wrote the mini-review.
REFERENCES

1. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat. (1995) 154:8–20. doi: 10.1159/000147748

2. Zheng X, Carstens J, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. (2015) 527:525–30. doi: 10.1038/nature16064

3. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong STC, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. (2015) 527:7579–89. doi: 10.1038/nature15748

4. Phan KD, Croteau LP, Kam JW, Kania A, Cloutier JF, Butler SL. Neogenin may functionally substitute for DCC in chicken. PLOS ONE. (2011) 6:e22072. doi: 10.1371/journal.pone.0022072

5. Mehlen P, Goldschneider D. Dependence receptors: a new paradigm in cell signalling and cancer therapy. Oncogene. (2010) 29:1865–82. doi: 10.1038/onc.2010.13

6. Mehlen P, Lamlbi F. Role of netrin-1 and netrin-1 dependence receptors in colorectal cancers. Brit J Cancer. (2005) 93:1–6. doi: 10.1038/sj.bjc.6602656

7. Rodrigues S, De Wever O, Bruyneel E, Rooney RI, Gepash C. Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis. Oncogene. (2007) 26:3651–25. doi: 10.1038/sj.onc.1210347

8. Sun K, Wu, C, Cornejo JP, Kennedy TE. Netrins: versatile extracellular cues with diverse functions. Development. (2011) 138:2153–69. doi: 10.1242/dev.044529

9. Force T, Ye X, Granger L, Corset V, Shn H, Bredesen D, et al. The dependence receptor DCC defines an alternative mechanism for caspase activation. Proc Nat Acad Sci USA. (2001) 98:3416–21. doi: 10.1073/pnas.051378298

10. Zhang QS, Liang F, Ke Y, Hsu YY, Li MC, Li YY, et al. Overexpression of neogenin inhibits cell proliferation and induces apoptosis in human MDA-MB-231 breast carcinoma cells. Oncol Rep. (2015) 34:256–8. doi: 10.3892/or.2015.4004

11. Kang DS, Yang YR, Lee C, Park BW, Park KIL, Seo JK, et al. Netrin-1/DCC-mediated PLC gamma 1 activation is required for axon guidance and brain structure development. EMBO Rep. (2018). 11:e46250. doi: 10.15252/embr.201948117

12. Weliniarz Q, Morel MP, Pourchet O, Gallea C, Lamy JC, Cincotta M, et al. Non cell-autonomous role of DCC in the guidance of the corticospinal tract at the midline. Sci Rep. (2017) 7:410. doi: 10.1038/s41598-017-00514-2

13. Van Damme J, Debeluy M, Deleer M, Ghezzi H, Thebaud C, Laval A, et al. Aspirin-induced histone acetylation in endothelial cells suppresses inflammation and albuminuria through suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice. Anat Rec. (2018) 211:1991–2002. doi: 10.1002/ar.24074

14. Batlle C, Hinck L, Nishiyama M, Poo MM, Tessier-Lavigne M, Stein E. Deletion of netrin-1 converting enzyme DCC family receptors converts netrin-induced growth cone attraction to repulsion. Cell. (1999) 99:927–41. doi: 10.1016/S0092-8674(00)80804-1

15. Chen J, Liu H, Zhang Y, Chen H, Zheng M, Lin P, et al. Netrin-1 prevents rat primary cortical neurons from apoptosis via the DCC/ERK pathway. Front Cell Neurosci. (2017) 11:387. doi: 10.3389/fncel.2017.00387

16. Finci L, Zhang Y, Meijers R, Wang J-H. Signaling mechanism of the netrin-1 dependence receptors and EMT protein expression. Brit J Pharmacol. (2015) 172:3548–64. doi: 10.1111/bph.13144

17. Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, Vieira RH, Lopes CS. The non-cell-autonomous role of DCC in the guidance of the corticospinal tract at the midline. Sci Rep. (2013) 3:173–5. doi: 10.1038/srep00215

18. Hong K, Hinck L, Nishiyama M, Poo MM, Tessier-Lavigne M, Stein E. A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. Cell. (1999) 99:927–41. doi: 10.1016/S0092-8674(00)80804-1

19. Hedgecock EM, Culotti JG, Hall DH. The unc-5, unc-6, and unc-54 genes guide circumferential migrations of pioneer axons and mesodermal cells on the epidermis in C. elegans. Neuron. (1990) 461:85. doi: 10.1016/0896-6273(90)90444-K

20. Fitamant J, Guenebeaud C, Cosieux MM, Guix C, Trilleux I, Scoazec JY, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Nat Acad Sci USA. (2008) 105:4850–5. doi: 10.1073/pnas.0709810105

21. Stone TW, Darlington LG, Forrest CM, McPherson M, Darlington LG, et al. Selective depletion of tumour suppressors deleted in colorectal cancer (DCC) and neogenin by environmental and endogenous serine proteases: linking diet and cancer. BMC Cancer. (2016) 16:772. doi: 10.1186/s12885-016-2795-y

22. Stone TW, Darlington LG. Microbial carcinogenic toxins and dietary anti-cancer protectants. Cell Mol Life Sci. (2017) 74:2627–43. doi: 10.1007/s00018-017-2487-z

23. Stone TW, McPherson M, Darlington LG. Obesity and cancer: existing and new hypotheses for a causal connection. EBioMedicine. (2018) 30:14–28. doi: 10.1016/j.ebiom.2018.02.022

24. McNair K, Forrest CM, Vincenten M, Darlington LG, Stone TW. Serine protease modulation of dependence receptors and EMT protein expression. Cancer Biol Ther. (2019) 20:343–69. doi: 10.1080/15384047.2018.1529190

25. Lopes FF, da Costa Miguel MC, Amaral Pereira ALA, Nogueira da Cruz MCF, Freitas RDA, Pinto LP, et al. Changes in immune-expression of E-cadherin and beta-catenin in oral squamous cell carcinoma with and without nodal metastasis. Ann Diagn Pathol. (2009) 13:22–9. doi: 10.1016/j.anndiagpath.2008.07.006

26. Jeevan DS, Cooper JB, Braun A, Murali R, Jhanwar-Unival M. Molecular pathway mediating metastases to the brain via EMT: genes, proteins and functional analysis. Anticancer Res. (2016) 36:523–32.

27. Rosado P, Lequerica-Fernandez P, Fernandez S, Alonza E, Villallain L, de Vicente JC. E-cadherin and beta-catenin expression in well-differentiated and moderately-differentiated oral squamous cell carcinoma: relations with clinical variables. Br J Oral Maxillo Surg. (2013) 51:149–56. doi: 10.1016/j.bjoms.2012.03.018

28. Sawada K, Misra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakov M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha5-integrin, which is a therapeutic target. Cancer Res. (2008) 68:2329–39. doi: 10.1158/0008-5472.CAN-07-5167

29. Serino D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. (2008) 68:989–97. doi: 10.1158/0008-5472.CAN-07-2017

30. Duband JL, Monier F, Delannet M, Newgreen D. Epithelium-mesenchyme transition during neural crest development. Acta Anat. (1995) 154:63–78. doi: 10.1159/000147753

31. Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, Vieira RH, Lopes CS. Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours. Gynecol Obstet Invest. (2005) 60:75–83. doi: 10.1159/000084614
38. Matos AJF, Lopes C, Carvalheira J, Santos M, Rutteman GR, Gartner F. E-cadherin expression in ovarian malignant mammary tumours: Relationship to other clinico-pathological variables. J Comp Pathol. (2006) 134:182–9. doi: 10.1016/j.jcpath.2005.10.004

39. Daugaard I, Sanders KJ, Idica A, Vittayarukskul K, Hamdorf M, Krog JD, et al. mir-151a induces partial EMT by regulating E-cadherin in NSCLC cells. Oncogenesis. (2017) 6:e366. doi: 10.1038/onsc.2017.66

40. Fite K, Gomez-Cambronero J. Down-regulation of MicroRNAs (MiRs) blocks the self-renewal of cancer stem cells and suppresses tumorigenesis. Mod Pathol (2015) 28:1038–47. doi: 10.1038/modpathol.2015.205

41. Zhao P, Guo SJ, Tu T, Di LJ, Zha XJ, et al. Grh13 induces human epithelial tumor cell migration and invasion via down-regulation of E-cadherin. Acta Biochim Biophys Acta. (2016) 48:266–74. doi: 10.1016/j.abbm.2001

42. Lin SY, Xia W, Wang JC, Kwong KY, Sbohn B, Wen Y, et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. (2000) 97:2462–6. doi: 10.1073/pnas.060025397

43. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecesas M, Castells A, Postigo A. beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Nat Acad Sci USA. (2011) 108:19204–9. doi: 10.1073/pnas.1011877108

44. Bakker ERM, Hoekstra E, Franken PF, Helvenstein W, van Deurzen CHM, van Veelen W, et al. Beta-catenin signalling dosage dictates tissue-specific tumor predisposition in APC-driven cancer. Oncogene. (2013) 32:4759–85. doi: 10.1038/onc.2012.449

45. Baimas A, Yu Z, Weinberger PM, Markakis S, Kowalski D, Camp RL, et al. Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with beta-catenin levels and outcome in patients with epithelial ovarian cancer. Ann Oncol. (2006) 17:1797–802. doi: 10.1093/annonc/mdj310

46. Dorfman T, Pollak Y, Sohotnik R, Coran AG, Bejar J, et al. Enhanced intestinal epithelial cell proliferation in diabetic rats correlates with beta-catenin accumulation. J Endocrinol. (2012) 226:135–43. doi: 10.1530/JOE-12-0725

47. Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, et al. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. (2013) 34:530–8. doi: 10.1093/carcin/bgs371

48. Liu Y, Ye X, Zhang J-B, Ouyang H, Shen Z, Wu Y, et al. PROX1 promotes hematopoietic carcinoma proliferation and sorafenib resistance by enhancing beta-catenin expression and nuclear translocation. Oncol Rep. (2015) 34:5524–35. doi: 10.1080/10789374.2015.103751

49. Qiu YM, Yuan RF, Zhang SH, Yuan RF, Zhang SH, Chen LF, Huang D, Hao HB, et al. Beta-catenin expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behaviour. Ann J Pathol. (1997) 150:483–95.

50. Yoneyama MS, Hatakeyama S, Habuchi T, Inoue T, Nakamura T, Fuyu T, et al. Vimentin intermediate filament and plectin provide a scaffold for invadopodia, facilitating cancer cell invasion and extravasation for metastasis. Europ J Cell Biol. (2014) 93:157–69. doi: 10.1016/j.ejcb.2014.03.002

51. Ozgunen BY, Karaçetin D, Kabukçuoglu F, Taskin T, Yener S. Beta-3-integrin expression of circulating tumor cells and correlation with clinical behavior. Turk J Haematol. (2016) 33:175–81. doi: 10.5753/tjha.2016.62870

52. Trivanovic D, Jaukovic A, Kresti J, Nikolic S, Djordjevic IO, Kukolj T, et al. Inflammatory cytokines prime adipose tissue mesenchymal stem cells to enhance malignancy of MCF-7 breast cancer cells via Transforming Growth Factor-beta 1. JUBMB Life. (2016) 68:190–200. doi: 10.1002/jub.1473

53. Messi E, Florian MC, Caccia C, Zanisi M, Maggi R. Retinoic acid induces human neuroblastoma cell migration and invasiveness: effects on DCX, L1, neurofilaments-68 and vimentin expression. BMC Cancer. (2008) 8:30. doi: 10.1186/1471-2407-8-30

54. Polioudaki H, Agelaki S, Chiotaki R, Politaki E, Mavrodis D, Matikas A, et al. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical
characteristics and outcome of patients with metastatic breast cancer. *BMC Cancer.* (2015) 15:399. doi: 10.1186/s12885-015-1386-7

74. Lin VCL, Jin RX, Tan PH, Aw SE, Woon CT, Bay BH. Progestrone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. *Am J Pathol.* (2003) 162:1781–7. doi: 10.1016/S0002-9440(06)6313-1

75. Chaturvedi V, Fourrier-Level A, Cooper HM, Murray MJ, Loss of Neogenin1 in human colorectal carcinoma cells causes a partial EMT and wound-healing response. *Sci Rep.* (2019) 9:4110. doi: 10.1038/s41598-019-40866-y

76. Campbell K, Rossi F, Adams J, Pitsidianiaki I, Barriga FM, Garcia-Quere J, et al. Collective cell migration and metastases induced by an epithelial-to-mesenchymal transition in Drosophila intestinal tumors. *Nat Commun.* (2019) 24:2311. doi: 10.1038/s41467-019-10269-y

77. Aiello NM, Maddipati R, Norgard RJ, Balli D, Li JY, Yuan S, et al. Distinct Roles for Wnt-4 and Wnt-11 during retinoic acid-induced neural differentiation. *Stem Cells.* (2011) 29:1491–53. doi: 10.1002/stem.562

78. Lin VCL, Jin RX, Tan PH, Aw SE, Woon CT, Bay BH. Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. *Am J Pathol.* (2003) 162:1781–7. doi: 10.1016/S0002-9440(06)6313-1

79. Agnoletto C, Corra F, Minotti L, Baldassari E, Crudelle F, Cook WJ, et al. Heterogeneity in circulating tumor cells: the relevance of the stem-cell subset. *Cancers.* (2019) 11:483. doi: 10.3390/cancers11040483

80. Pallegr N, Garland CJ, Mahendralingam M, Viloria-Petit AM, Christian SL. A novel 3-dimensional co-culture method reveals a partial mesenchymal to epithelial transition in breast cancer Cells Induced by adipocytes. *J Mammm Biol Neoplasia.* (2019) 26:85–97. doi: 10.1080/10911318.19420--4

81. Wilson MR, Reske JJ, Holladay J, Wilber GE, Rhodes M, Koeman J, et al. ARID1A and P53 kinase pathway mutations in the endome trium drive epithelial differentiation and collective invasion. *Nat Commun.* (2019) 10:3554. doi: 10.1038/s41467-019-11403-6

82. Almale L, Garcia-Alvaro M, Martinez-Palacian A, Garcia-Bravo M, LaczanoiMturenu R, Addante A, et al. Met-signaling is essential for mouse adult liver progenitor cells expansion after transforming growth factor-beta-induced epithelial-mesenchymal transition and regulates cell phenotypic switch. *Stem Cells.* (2019) 37:1108–18. doi: 10.1002/stem.3038

83. Kato H, Zhou Y, Asanoma K, Kondo H, Yoshikawa Y, Watanabe K, et al. Epithelial-mesenchymal transition in Drosophila intestinal tumors. *Nat Commun.* (2019) 10:2911. doi: 10.1038/s41467-019-10269-y

84. Elizalde C, Campa VM, Caro M, Schlangen K, Maria A, Aransay AM, et al. Antisense RNA to the putative tumor-suppressor gene DCC transforms rat-1 fibroblasts. *Oncogene.* (1992) 7:569–75. doi: 10.1016/S0950-9232(05)00883-8

85. Saegusa M, Hashimura M, Hara A, Okayasu I. Loss of expression of the DCC gene-product in cellular-differentiation and colorectal tumorigenes is. *Mol Cell Endocrinol.* (1992) 7:553–61.

86. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: focus on morphologically evident mesenchymal phenotypic transition. *Pathology.* (2015) 51:494–501. doi: 10.1016/j.pathol.2015.04.004

87. Bure IV, Nemtsova MV, Zalevskiy DV, Roles of E-cadherin and noncoding RNAs in the epithelial-mesenchymal transition and progression in gastric cancer. *Int J Mol Cell.* (2019) 20:2870. doi: 10.3390/jms122870
HT-29 cells and associates with ezrin. *Eur J Cell Biol.* (2006) 85:769–83. doi: 10.1016/j.ejcb.2006.02.013

113. Hedrick L, Cho KR, Boyd J, Risinger J, Vogelstein B. DCC - A tumor-suppressor gene expressed on the cell-surface. *Cold Spring Harb Symp Quant Biol.* (1992) 57:345–51. doi: 10.1101/SQB.1992.057.01.039

114. Pert M, Gan M, Saint R, Murray MJ. Netrins and Frazzled/DCC promote the migration and mesenchymal to epithelial transition of *Drosophila* midgut cells. *Biol Open.* (2015) 4:233–43. doi: 10.1242/bio.201410827

115. Gal R, Sadikov E, Sulkes J, Klein B, Koren R. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

116. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *New Engl J Med.* (1996) 335:1727–32. doi: 10.1056/NEJM199612053352303

117. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

118. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

119. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

120. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

121. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

122. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

123. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

124. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

125. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

126. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

127. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

128. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, et al. The DCC protein and prognosis in colorectal cancer. *Dis Colon Rectum.* (2004) 47:1216–24. doi: 10.1007/s10350-004-0552-9

Conflict of Interest: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Stone. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.